Dexcom

DexCom, Inc.

Company type	Public
Industry	Healthcare, Medical devices
Founded	1999
Founder	Scott Glenn, John Burd, Lauren Otsuki, Ellen Preston, Bret Megargel
Headquarters	San Diego , United States
Area served	Worldwide
Key people	Kevin Sayer (CEO)
Products	Continuous glucose monitoring devices
Number of employees	10,300 (2024)
Website	www.dexcom.com

DexCom, Inc. is a U.S.-based healthcare firm focused on designing, producing, and distributing continuous glucose monitoring (CGM) devices tailored for diabetes care. Its headquarters are located in San Diego, California, with manufacturing operations situated in Mesa, Arizona; Batu Kawan, Malaysia; and Athenry, Ireland.

History

Established in 1999 by Scott Glenn, John Burd, Lauren Otsuki, Ellen Preston, and Bret Megargel, Dexcom received FDA clearance in 2006 for its inaugural CGM product, the Dexcom STS, which provided glucose monitoring over a three-day period. The company enhanced its offerings in 2007 with the introduction of the Seven CGM system, extending sensor lifespan to seven days and delivering improved precision. In 2008, Dexcom formed strategic alliances with Insulet Corporation, Animas Corporation, and Edwards Lifesciences to broaden the scope of CGM applications.

In 2009, the company released the Seven Plus CGM system after obtaining FDA and CE mark certifications. Although collaboration with Insulet ended in 2013, Dexcom entered into a non-exclusive partnership with Tandem Diabetes Care in 2015 to incorporate its G5 and G6 systems into Tandem’s insulin pumps. The G5 system gained FDA approval as a standalone device in 2016, followed by the G6 in 2018.

By 2012, the G4 Platinum series had secured FDA and CE mark clearances and was distinguished by improved hypoglycemia detection accuracy and an extended signal transmission range. Pediatric usage received approval in 2014. The G4 Platinum with Share launched in 2015 enabled glucose data sharing through smartphone applications. Later that year, the G5 system introduced Bluetooth connectivity for mobile devices and earned CE marking.

Dexcom became a publicly traded company in 2005 on the Nasdaq Global Select Market under the ticker symbol DXCM. In April 2020, it was included in the Nasdaq-100 index. The most recent product achievement was the FDA approval of the G7 CGM system in December 2022, noted as the most precise continuous glucose monitor authorized within the United States.

As of 2024, Dexcom reported revenues totaling $4.03 billion alongside an operating income of $600 million and net earnings of $576 million. The organization employs roughly 10,300 individuals worldwide under the leadership of CEO Kevin Sayer.

Awards and recognition

In October 2024, Time Magazine recognized Dexcom Stelo’s over-the-counter glucose monitoring device as one of that year’s top inventions.

Partnerships

• In 2015, Dexcom collaborated with Google Life Sciences (later rebranded as Verily) to co-develop the Dexcom G7 continuous glucose monitor.
• Also during 2015, Dexcom entered a non-exclusive agreement with Tandem Diabetes Care, Inc., facilitating integration of its G5 and G6 CGM systems into Tandem’s insulin pump devices. Tandem secured FDA clearance in December 2019 for Control-IQ, a closed-loop system combining the t:slim X2 pump with Dexcom G6 to automate insulin delivery for individuals managing Type 1 diabetes.
• June 2019 saw Dexcom partner with Companion Medical to enable interoperability between Dexcom CGM data and Companion’s InPen insulin management software.
• In January 2020, Dexcom joined forces with Livongo, incorporating Dexcom G6 data into Livongo’s digital platform for chronic disease management.
• February 2020 marked a global agreement between Dexcom and Insulet Corporation to integrate Dexcom CGM technology with Insulet’s tubeless Pod device within the Omnipod Horizon System for automated insulin delivery via smartphone or algorithmic control.
• In March 2020, Dexcom teamed up with Welldoc to embed Dexcom G6 data into BlueStar, a digital platform designed for diabetes management.
• November 2024 featured a strategic partnership announcement between Dexcom and Oura, aimed at enriching their shared digital health ecosystem through data collaboration.

Venture capital division

At the beginning of 2021, Dexcom introduced Dexcom Ventures, a corporate venture capital initiative focused on innovative continuous glucose monitoring solutions and devices that analyze various biomarkers. This investment arm has also allocated funds to cybersecurity technologies designed for medical device software, aligning with the company’s strategic goal to strengthen its product portfolio and expand its market presence.

See also

• Dexcom CGM